Wharton Jelly derived mesenchymal stem cells (Medical University of Warsaw)

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameWharton Jelly derived mesenchymal stem cells (Medical University of Warsaw)

Drug Alias NameWJMSC

ClassificationCell and gene therapy > Cell therapy > Source of cells > Wharton's Jelly-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsAmyotrophic Lateral SclerosisOsteoarthritis, KneeOsteoarthritis, Hip +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMedical University Of Warsaw

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedical University Of Warsaw Polski Bank Komorek Macierzystych SA

Active IndicationsN/A

Inactive IndicationsAmyotrophic Lateral SclerosisOsteoarthritis, KneeOsteoarthritis, Hip +[4]

Other Information

ATC CodeN/A